Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients wuth severe angina of effort

M. D. Winniford, R. L. Huxley, L. D. Hillis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

This study compared propranolol alone with a combination of propranolol and verapamil in patients with severe, limiting angina of effort. Accordingly, 13 men (average age 57 years) with severe angina were enrolled in a study of 7 weeks' duration. Throughout the study, a stable dose of propranolol (295 ± 83 [mean ± standard deviation] mg/kg) was administered. In addition to propranolol therapy, each patient was given 2 weeks of up-titration of open label verapamil, 1 week of verapamil down-titration and two 2 week periods of randomized, double-blind therapy, one of placebo and the other of verapamil (431 ± 77 mg/day). A propranolol-verapamil combination caused a decline in anginal episodes/week (7.3 ± 6.9/week during propranolol-placebo, 4.7 ± 5.0 week during propranolol-verapamil, p = 0.03) and nitroglycerin tablets used/week (7.6 ± 6.6/week during propranolol-placebo, 4.4 ± 4.2/week during propranolol-verapamil, p = 0.008). With propranolol-placebo, all 13 patients had angina after 4.6 ± 2.1 minutes of supine bicycle exercise. With propranolol-verapamil, five had no angina with exercise even though their duration of exercise increased; in the other eight, time to angina increased (from 4.0 ± 1.5 minutes with propranolol-placebo to 5.3 ± 1.6 minutes with propranolol-verapamil, p = 0.01). A propranolol-verapamil combination induced no change in rest or peak exercise left ventricular volumes or ejection fraction (assessed by equilibrium gated blood pool scintigraphy). With propranolol-verapamil, four patients had PR interval prolongation, and two had fatigue and dyspnea. In addition, two had marked sinus bradycardia with junctional escape rhythm that was resolved with a reduction of verapamil dosage. No patient developed congestive heart failure or high degree atrioventricular block. Thus, a combination of propranolol and verapamil is superior to propranolol alone in patients with severe, limiting angina, but such a combination must be used cautiously because of potentially serious adverse effects.

Original languageEnglish (US)
Pages (from-to)492-498
Number of pages7
JournalJournal of the American College of Cardiology
Volume1
Issue number2 I
StatePublished - 1983
Externally publishedYes

Fingerprint

Verapamil
Propranolol
Placebos
Exercise
Gated Blood-Pool Imaging
Atrioventricular Block
Nitroglycerin
Bradycardia
Dyspnea
Tablets
Fatigue

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients wuth severe angina of effort. / Winniford, M. D.; Huxley, R. L.; Hillis, L. D.

In: Journal of the American College of Cardiology, Vol. 1, No. 2 I, 1983, p. 492-498.

Research output: Contribution to journalArticle

@article{a8153c69c3fb429b8a88312c3f0052ca,
title = "Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients wuth severe angina of effort",
abstract = "This study compared propranolol alone with a combination of propranolol and verapamil in patients with severe, limiting angina of effort. Accordingly, 13 men (average age 57 years) with severe angina were enrolled in a study of 7 weeks' duration. Throughout the study, a stable dose of propranolol (295 ± 83 [mean ± standard deviation] mg/kg) was administered. In addition to propranolol therapy, each patient was given 2 weeks of up-titration of open label verapamil, 1 week of verapamil down-titration and two 2 week periods of randomized, double-blind therapy, one of placebo and the other of verapamil (431 ± 77 mg/day). A propranolol-verapamil combination caused a decline in anginal episodes/week (7.3 ± 6.9/week during propranolol-placebo, 4.7 ± 5.0 week during propranolol-verapamil, p = 0.03) and nitroglycerin tablets used/week (7.6 ± 6.6/week during propranolol-placebo, 4.4 ± 4.2/week during propranolol-verapamil, p = 0.008). With propranolol-placebo, all 13 patients had angina after 4.6 ± 2.1 minutes of supine bicycle exercise. With propranolol-verapamil, five had no angina with exercise even though their duration of exercise increased; in the other eight, time to angina increased (from 4.0 ± 1.5 minutes with propranolol-placebo to 5.3 ± 1.6 minutes with propranolol-verapamil, p = 0.01). A propranolol-verapamil combination induced no change in rest or peak exercise left ventricular volumes or ejection fraction (assessed by equilibrium gated blood pool scintigraphy). With propranolol-verapamil, four patients had PR interval prolongation, and two had fatigue and dyspnea. In addition, two had marked sinus bradycardia with junctional escape rhythm that was resolved with a reduction of verapamil dosage. No patient developed congestive heart failure or high degree atrioventricular block. Thus, a combination of propranolol and verapamil is superior to propranolol alone in patients with severe, limiting angina, but such a combination must be used cautiously because of potentially serious adverse effects.",
author = "Winniford, {M. D.} and Huxley, {R. L.} and Hillis, {L. D.}",
year = "1983",
language = "English (US)",
volume = "1",
pages = "492--498",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2 I",

}

TY - JOUR

T1 - Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients wuth severe angina of effort

AU - Winniford, M. D.

AU - Huxley, R. L.

AU - Hillis, L. D.

PY - 1983

Y1 - 1983

N2 - This study compared propranolol alone with a combination of propranolol and verapamil in patients with severe, limiting angina of effort. Accordingly, 13 men (average age 57 years) with severe angina were enrolled in a study of 7 weeks' duration. Throughout the study, a stable dose of propranolol (295 ± 83 [mean ± standard deviation] mg/kg) was administered. In addition to propranolol therapy, each patient was given 2 weeks of up-titration of open label verapamil, 1 week of verapamil down-titration and two 2 week periods of randomized, double-blind therapy, one of placebo and the other of verapamil (431 ± 77 mg/day). A propranolol-verapamil combination caused a decline in anginal episodes/week (7.3 ± 6.9/week during propranolol-placebo, 4.7 ± 5.0 week during propranolol-verapamil, p = 0.03) and nitroglycerin tablets used/week (7.6 ± 6.6/week during propranolol-placebo, 4.4 ± 4.2/week during propranolol-verapamil, p = 0.008). With propranolol-placebo, all 13 patients had angina after 4.6 ± 2.1 minutes of supine bicycle exercise. With propranolol-verapamil, five had no angina with exercise even though their duration of exercise increased; in the other eight, time to angina increased (from 4.0 ± 1.5 minutes with propranolol-placebo to 5.3 ± 1.6 minutes with propranolol-verapamil, p = 0.01). A propranolol-verapamil combination induced no change in rest or peak exercise left ventricular volumes or ejection fraction (assessed by equilibrium gated blood pool scintigraphy). With propranolol-verapamil, four patients had PR interval prolongation, and two had fatigue and dyspnea. In addition, two had marked sinus bradycardia with junctional escape rhythm that was resolved with a reduction of verapamil dosage. No patient developed congestive heart failure or high degree atrioventricular block. Thus, a combination of propranolol and verapamil is superior to propranolol alone in patients with severe, limiting angina, but such a combination must be used cautiously because of potentially serious adverse effects.

AB - This study compared propranolol alone with a combination of propranolol and verapamil in patients with severe, limiting angina of effort. Accordingly, 13 men (average age 57 years) with severe angina were enrolled in a study of 7 weeks' duration. Throughout the study, a stable dose of propranolol (295 ± 83 [mean ± standard deviation] mg/kg) was administered. In addition to propranolol therapy, each patient was given 2 weeks of up-titration of open label verapamil, 1 week of verapamil down-titration and two 2 week periods of randomized, double-blind therapy, one of placebo and the other of verapamil (431 ± 77 mg/day). A propranolol-verapamil combination caused a decline in anginal episodes/week (7.3 ± 6.9/week during propranolol-placebo, 4.7 ± 5.0 week during propranolol-verapamil, p = 0.03) and nitroglycerin tablets used/week (7.6 ± 6.6/week during propranolol-placebo, 4.4 ± 4.2/week during propranolol-verapamil, p = 0.008). With propranolol-placebo, all 13 patients had angina after 4.6 ± 2.1 minutes of supine bicycle exercise. With propranolol-verapamil, five had no angina with exercise even though their duration of exercise increased; in the other eight, time to angina increased (from 4.0 ± 1.5 minutes with propranolol-placebo to 5.3 ± 1.6 minutes with propranolol-verapamil, p = 0.01). A propranolol-verapamil combination induced no change in rest or peak exercise left ventricular volumes or ejection fraction (assessed by equilibrium gated blood pool scintigraphy). With propranolol-verapamil, four patients had PR interval prolongation, and two had fatigue and dyspnea. In addition, two had marked sinus bradycardia with junctional escape rhythm that was resolved with a reduction of verapamil dosage. No patient developed congestive heart failure or high degree atrioventricular block. Thus, a combination of propranolol and verapamil is superior to propranolol alone in patients with severe, limiting angina, but such a combination must be used cautiously because of potentially serious adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0020574367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020574367&partnerID=8YFLogxK

M3 - Article

C2 - 6338082

AN - SCOPUS:0020574367

VL - 1

SP - 492

EP - 498

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2 I

ER -